Premium
Should Immune‐Enhancing Formulations Be Used for Patients With Acute Respiratory Distress Syndrome?
Author(s) -
Roosevelt Hannah
Publication year - 2016
Publication title -
nutrition in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.725
H-Index - 71
eISSN - 1941-2452
pISSN - 0884-5336
DOI - 10.1177/0884533616654868
Subject(s) - medicine , ards , acute respiratory distress , intensive care medicine , immune system , enteral administration , immunology , lung , parenteral nutrition
The potential for regulating immune function in acute respiratory distress syndrome (ARDS) through enteral‐administered anti‐inflammatory lipids has generated much interest over the past 20 years. Yet recommendations remain inconclusive regarding the utilization of ω‐3 fatty acids in patients with ARDS and acute lung injury (ALI). Studies are limited in number, with differing methods, small sample sizes, and conflicting results, making recommendations difficult to interpret.